Monthly Archives: March 2011
Upcoming Webinar: How Can I Get Involved in Ovarian Cancer Clinical Trials?
This 90-minute session will cover the basics of cancer clinical trials, including key risks and benefits, myths about clinical trials and how people can be referred to a cancer clinical trial. The webinar will be led by Margo Michaels, Executive … Continue reading
Cost-Effective Analysis of Bevacizumab for Ovarian Cancer
A study published in the Journal of Clinical Oncology concludes that “[t]he addition of bevacizumab to standard chemotherapy in patients with advanced ovarian cancer is not cost effective.” The study analyzed costs of treating women with advanced ovarian cancer according … Continue reading
Carbo/Doxil in elderly patients
BACKGROUND: CALYPSO (CAeLYx in Platinum Sensitive Ovarian) patients compared carboplatin-pegylated liposomal doxorubicin (C-PLD) with carboplatin-paclitaxel (C-P) in patients with late-relapsing recurrent ovarian cancer (ROC). We analyzed outcomes in patients <70 years. PATIENTS AND METHODS: Nine hundred and seventy-six patients with … Continue reading
A Study of Ovarian Cancer Symptoms, and Physician Responses
BACKGROUND: A study was undertaken to identify the diagnostic approaches that primary care physicians and gynecologists undertake in women with symptoms associated with ovarian cancer. METHODS: A vignette-based survey was mailed to 3200 primary care physicians from the American Medical … Continue reading
Phase II Trial of Phenoxodial Complete
INTRODUCTION: Chemoresistance is a major limitation in the treatment of ovarian cancer. Phenoxodiol is a novel biomodulator capable of reversing chemoresistance in vitro and in vivo. In this study, we determined the safety and efficacy of intravenous phenoxodiol in combination … Continue reading
Issue Three of The Teal Journal Now Available
The third issue of The Teal Journal: The Ovarian Cancer National Alliance Periodical of Progress, was published last week on www.tealjournal.org. In this issue, you will find news of the latest ovarian cancer research, as well as answers to your … Continue reading
Posted in Blog Leave a comment
Health Reform One Year Later
Today marks the one-year anniversary of the enactment of the health reform bill, the Patient Protection and Affordable Care Act. Over the past year, numerous federal agencies have begun to implement provisions of the bill that benefit women with ovarian … Continue reading
Alliance President Featured in Cure Today
Board President of the Ovarian Cancer National Alliance, Annette Leal Mattern, is featured in an article on Cure Today, Breaking Out of the Silence. Mattern is a 24-year survivor of ovarian cancer. She retired from US WEST/Qwest as Vice President … Continue reading
Posted in Blog Leave a comment
Board President Emerita Judith Abrams Honored for Her Philanthropy and Mentorship
Judith S. Abrams, President Emerita of the Ovarian Cancer National Alliance, will be honored tonight at the first annual Women Mentoring and Philanthropy Global Summit in Atlanta, GA. Judy is being honored as a philanthropist and mentor dedicated to ovarian … Continue reading
Posted in Blog Leave a comment
Letter from CEO Karen Orloff Kaplan in the Washington Post
A letter from our CEO, Karen Orloff Kaplan, to the Washington Post explains the importance of the Defense Department’s Ovarian Cancer Research Program. Her letter, published March 18, 2011, is included below. The Pentagon’s Valuable Cancer Research I am one … Continue reading
Posted in News Leave a comment
ESAs Linked to Ovarian Cancer Mortality (Medpage)
A study presented at the Society for Gynecologic Oncology annual meeting in March, 2011 showed that women treated with ESAs had higher rates of ovarian cancer recurrence and death. ESAs (erythropoetin stimulating agents) are used to promote the growth of … Continue reading
